Roszdravnadzor checks reports of the death of a child against the background of taking Zolgensma

This was reported by the press service of the department.

“Roszdravnadzor is conducting a comprehensive assessment of the circumstances of the causes of death of a child while taking Zolgensma in Russia, as previously reported in the media,” Roszdravnadzor said.

Earlier, RIA Novosti, citing a statement by the Swiss drug manufacturer Novartis, stated that two children in Russia and Kazakhstan died while treating spinal muscular atrophy with the drug Zolgensma.

In July, it was reported that the drug Zolgensma, used to treat spinal muscular atrophy, officially appeared in Russia.